Roche’s RoActemra (tocilizumab) has been recommended in draft guidance for treating systemic juvenile idiopathic arthritis (JIA).
NICE recommended the treatment after Roche provided its Appraisal Committee with further requested clinical data and it agreed a revised Patient Access Scheme with the DH.
Professor Carole Longson, Health Technology Evaluation Centre Director at NICE, says the recommendation is “good news for children with systemic JIA and those caring for them.”
The draft recommendation is for the use of RoActemra in children aged 2 and over where specific previous treatments have not produced an adequate response.
However, in cases where those whose disease continues to respond to methotrexate or who have not been treated with methotrexate, RoActemra is not recommended as a treatment option.
“The discount agreed as part of the patient access scheme put forward by the manufacturer, in addition to the further information they provided at the Committee’s request, has enabled the Committee to recommend tocilizumab for systemic juvenile idiopathic arthritis in today’s draft guidance,” said Professor Longson.
“The draft guidance proposes that tocilizumab should be the treatment for children aged over 2 years and young people where their systemic JIA hasn’t responded well to other treatments.”